Dr Konstantinos Koskinas

Go Back


  • Bern University Hospital
  • location Switzerland

Konstantinos Koskinas is Attending Physician and Head of the Dyslipidemia Center in the Department of Cardiology at Bern University Hospital, Bern, Switzerland. After receiving his MD in 2004 from the Aristotle University of Thessaloniki, Thessaloniki, Greece, he completed research fellowships at Brigham and Women's Hospital, Harvard Medical School, Boston, USA, and Massachusetts Institute of Technology (MIT), Cambridge, USA, a clinical Cardiology fellowship at Hippokration University Hospital, Thessaloniki, Greece, and an interventional Cardiology fellowship at Bern University Hospital, Bern, Switzerland. Dr Koskinas’s main research interests include the risk factors of atherosclerosis, dyslipidaemias, intracoronary imaging, and coronary artery disease, and he is the Principal Investigator and Co-PI on the EVOPACS and PACMAN-AMI trials, respectively. A member of the 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) task force for the guidelines of the management of dyslipidaemia and the 2020-2022 ESC Committee for Clinical Practice Guidelines, he is a member of the European Association of Percutaneous Cardiovascular Intervention (EAPCI) and elected nucleus member of Population Science & Public Health section of the European Association of Preventive Cardiology (EAPC). Dr Koskinas was the recipient of the Young Investigator Award from the ESC in 2010, and the International Society of Atherosclerosis in 2009. He is an international editorial board member of EuroIntervention, the official journal of the EAPCI, and has published many peer-reviewed articles in international journals including Circulation, the Journal of the American College of Cardiology, the European Heart Journal, Atherosclerosis, and Arteriosclerosis, Thrombosis and Vascular Biology.

Dr Konstantinos Koskinas has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen and Sanofi.